Skip to main content
OpenTrials
Completed

NCT Number: NCT05175521

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disorders Nausea Nervous System Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HonorHealth Bob Bové Neuroscience Institute

Scottsdale, Arizona, 85251, United States

About this study

The main goal of this study is to examine the efficacy of (nausea reduction and time to use of other anti-nausea medications) and side effects of inhaled isopropyl alcohol vapor (IAV) for treating nausea among migraine patients using a double blind randomized control methodology. IAV is being compared inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) which has not shown benefit for treating nausea or migraine and is therefore considered placebo in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 to 65 years old with nausea associated migraines at least twice per month

Exclusion criteria

  • Patients <18 or >65 years old
  • Patients without a diagnosis of acute migraine

Treatment and study plan

Eucalyptus Oil Scent

Other

Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack

Isopropyl Alcohol Vapors

Other

Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack

Primary outcomes

  1. Change of Severity of Nausea on Nausea Scale

    Time frame: ½ hour or to the end of treatment

    Change in Nausea, modified visual analog score from 0-10 with 10 severe nausea with vomiting, 5 moderate nausea, 1 mild nausea and 0 no nausea.

Secondary outcomes

  1. Side effects associated with interventional substance

    Time frame: ½ hour, but likely less than 2 hours

    Patient written report

  2. Use of anti-nausea medication/Time to use of anti-nausea medication

    Time frame: ½ hour or to the end of treatment

    Did using IAV vs eucalyptus oil change the time until use of oral anti-emetic?

  3. Time to Clinically Relevant Nausea Change

    Time frame: ½ hour or to the end of treatment

    Did IAV vs eucalyptus oil reduce the amount of time the patient experienced nausea with their migraine?

Sponsors and collaborators

Lead sponsor

HonorHealth Research Institute

Other

Registry information

Official study title

Double Blind Randomized Control Trial of Inhaled Isopropyl Alcohol Vapors Versus Inhaled Eucalyptus Scent for the Treatment of Nausea Associated With Acute Migraine

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Jan 3, 2022
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.